scholarly journals Cost-utility Analysis of Opportunistic and Systematic Diabetic Retinopathy Screening Strategies from the Perspective of the Brazilian Public Healthcare System

2019 ◽  
Vol 18 (1) ◽  
pp. 57-68 ◽  
Author(s):  
Ângela J. Ben ◽  
Jeruza L. Neyeloff ◽  
Camila F. de Souza ◽  
Ana Paula O. Rosses ◽  
Aline L. de Araujo ◽  
...  
2017 ◽  
Vol 20 (9) ◽  
pp. A724
Author(s):  
M Geitona ◽  
E Stamuli ◽  
S Giannakodimos ◽  
V Kimiskidis ◽  
V Kountouris ◽  
...  

2021 ◽  
Vol 10 (11) ◽  
pp. 2352
Author(s):  
Andrzej Grzybowski ◽  
Piotr Brona

Background: The prevalence of diabetic retinopathy (DR) is expected to increase. This will put an increasing strain on health care resources. Recently, artificial intelligence-based, autonomous DR screening systems have been developed. A direct comparison between different systems is often difficult and only two such comparisons have been published so far. As different screening solutions are now available commercially, with more in the pipeline, choosing a system is not a simple matter. Based on the images gathered in a local DR screening program we performed a retrospective comparison of IDx-DR and Retinalyze. Methods: We chose a non-representative sample of all referable DR positive screening subjects (n = 60) and a random selection of DR negative patient images (n = 110). Only subjects with four good quality, 45-degree field of view images, a macula-centered and disc-centered image from both eyes were chosen for comparison. The images were captured by a Topcon NW-400 fundus camera, without mydriasis. The images were previously graded by a single ophthalmologist. For the purpose of this comparison, we assumed two screening strategies for Retinalyze—where either one or two out of the four images needed to be marked positive by the system for an overall positive result at the patient level. Results: Percentage agreement with a single reader in DR positive and DR negative cases respectively was: 93.3%, 95.5% for IDx-DR; 89.7% and 71.8% for Retinalyze strategy 1; 74.1% and 93.6% for Retinalyze under strategy 2. Conclusions: Both systems were able to analyse the vast majority of images. Both systems were easy to set up and use. There were several limitations to the current pilot study, concerning sample choice and the reference grading that need to be addressed before attempting a more robust future study.


2014 ◽  
Vol 22 (1) ◽  
pp. 4-12 ◽  
Author(s):  
Ryo Kawasaki ◽  
Yoko Akune ◽  
Yoshimune Hiratsuka ◽  
Shunichi Fukuhara ◽  
Masakazu Yamada

PEDIATRICS ◽  
2006 ◽  
Vol 117 (Supplement 3) ◽  
pp. S287-S295 ◽  
Author(s):  
Aaron E. Carroll ◽  
Stephen M. Downs

2019 ◽  
Vol 2019 ◽  
pp. 1-7 ◽  
Author(s):  
Nguyen Xuan Thanh ◽  
Philip Jacobs ◽  
Jason Suggett ◽  
Andrew McIvor ◽  
Alan Kaplan

Background. The Aerobika® oscillating positive expiratory pressure (OPEP) device is a hand-held, drug-free medical device that has been shown to improve lung function and improve health-related quality of life in patients with chronic obstructive pulmonary disease (COPD). We estimated the cost-effectiveness of this device among postexacerbation COPD patients in the Canadian healthcare system. Methods. We performed a cost-utility analysis using a Markov model to compare both costs and outcome of patients with COPD who had recently experienced an exacerbation between 2 treatment arms: patients who used the Aerobika® device and patients who did not use the Aerobika® device. This cost-utility analysis included costs based on the Alberta healthcare system perspective as these represent Canadian experience. A one-year horizon with 12 monthly cycles was used. Results. For a patient after 1 year, the use of the Aerobika® device would save $694 in healthcare costs and produce 0.04 more in quality-adjusted life years (QALYs) in comparison with no positive expiratory pressure (PEP)/OPEP therapy. In other words, the economic outcome of the device was dominant (i.e., more effective and less costly). The probability for this device to be the dominant strategy was 72%. With a willingness to pay (WTP) threshold of $50,000 per QALY gained, the probability for the Aerobika® device to be cost-effective was 77%. Conclusions. Given one of the major treatment goals in the GOLD guidelines is to minimize the negative impact of exacerbations and prevent re-exacerbations, the Aerobika® OPEP device should be viewed as a potential component of a treatment strategy to improve symptom control and reduce the risk of re-exacerbations in patients with COPD.


Sign in / Sign up

Export Citation Format

Share Document